ライフサイエンスコーパス: core binding factor

1 inding sites for ETS-domain proteins and the core binding factor.

2 not affect the expression of osteocalcin and core binding factor.

3 s a DNA-binding subunit of the heterodimeric core-binding factor.

4 teins that either can or cannot activate the core binding factor 1 (CBF1) in 32D (clone 3) myeloblast

5 ptor gamma (PPARgamma), leptin, osteonectin, core binding factor 1 (CBFA1), and FBJ murine osteosarco

6 s studied include transcription factors like core binding factor 1 (Cbfa1), bone morphogenetic protei

7 Core-binding factor 1 (Cbfa1; also called Runx2) is a tr

8 on of the osteogenic markers osteocalcin and core-binding factor-1 genes, the latter of which is cons

9 We identified core-binding factor a1 binding to the runt domain bindin

10 on of both c-Fos and c-Jun in osteoblasts or core-binding factor a1 increased collagenase-3 promoter

11 hermore, overexpression of c-Fos, c-Jun, and core-binding factor a1 synergistically increased collage

12 ulted in the inability of c-Fos and c-Jun or core-binding factor a1 to increase collagenase-3 promote

13 Overexpression of Fra-2 and JunD repressed core-binding factor a1-induced collagenase-3 promoter ac

14 ed from patient platelet RNA exons 3 to 6 of core-binding factor A2 (CBFA2) cDNA, which encompasses t

15 -HSC function is highly reliant on continued core binding factor activity.

16 Not all patients with core binding factor acute myeloid leukemia (CBF-AML) dis

17 Timed-Sequential Induction in Patients With Core Binding Factor Acute Myeloid Leukemia and Treating

18 To identify cooperating lesions in core-binding factor acute myeloid leukemia, we performed

19 tance should provide important insights into core-binding factor acute myeloid leukemia.

20 Although core-binding factor-acute myeloid leukemia (CBF-AML) (t[

21 Core binding factor alpha (Cbfa) mRNA, expressed constit

22 RUNX1 (AML1) encodes the core binding factor alpha subunit of a heterodimeric tra

23 ion of the osteoblast differentiation factor core binding factor alpha-1 (Cbfa1) and several bone-ass

24 including Id1, Id2, and Id3, associate with core binding factor alpha-1 (Cbfa1) to cause diminished

25 Core binding factor alpha-1 (Cbfa1), a member of the run

26 lysis for gene expression (up to 10 days for core binding factor alpha-1 [Cbfa1], bone sialoprotein [

27 ne expression using Northern blot for Cbfal (core binding factor alpha-1); OCN (osteocalcin), OPN (os

28 Gene expression of core binding factor alpha-1, an osteoblast-specific tran

29 olyoma enhancer-binding protein (PEBP2alpha)/core-binding factor alpha (CBFA) class are key transacti

30 gene AML1, encoding the transcription factor core-binding factor alpha (CBFalpha).

31 tein (MEPE); bone markers: osteocalcin (OC), core-binding factor alpha 1 (CBFalpha1), and alkaline ph

32 Transcription factors of the AML (core binding factor-alpha/polyoma enhancer binding prote

33 Our results of the expression pattern of core binding factor alpha1 (Cbfa1), which binds to the r

34 inding activity of the transcription factor, core binding factor alpha1 (Cbfa1).

35 gerprint, marked by the transcription factor core binding factor alpha1.

36 proteins including the transcription factor core-binding factor alpha1 (Cbfa1).

37 the osteoblast-specific transcription factor core-binding factor alpha1 (Cbfa1).

38 imulated cells expressed increased levels of core-binding factor alpha1, osteocalcin, alkaline phosph

39 the osteoblast-specific transcription factor core-binding factor alpha1/Runx2.

40 We report that the Ets-1 partner protein core-binding factor alpha2 (CBFalpha2; also known as AML

41 Core-binding factor alpha2 (CBFalpha2; otherwise known a

42 hin AML and are usually reported together as core binding factor AML (CBF-AML).

43 16 to 60 years of age, excluding those with core binding factor AML and acute promyelocytic leukemia

44 In non-core binding factor AML, subclone formation was associat

45 For some AML categories, namely core-binding factor AML and/or cytogenetically normal AM

46 We suggest that patients with core-binding factor AML should be screened for mutKIT at

47 Although both heterodimeric subunits of core binding factors (AML1/RUNX1 and CBFbeta) essential

48 The core binding factors are a small family of transcription

49 Core binding factors are heterodimeric transcription fac

50 nx family members can interact with Cbfbeta (core-binding factor b, encoded by Cbfb), a role for Cbfb

51 f complex is composed of the unique cofactor core binding factor beta (CBF-beta) and canonical ligase

52 A related protein, known as core binding factor beta (CBFbeta) also binds to the RD

53 ene encodes a chimeric protein involving the core binding factor beta (CBFbeta) and the smooth-muscle

54 e Runt-related transcription factor 1 (RUNX)/core binding factor beta (CBFbeta) complexes.

55 sion between the transcription factor called core binding factor beta (CBFbeta) on 16q and a smooth m

56 DNA binding and heterodimerization with the core binding factor beta (CBFbeta) subunit.

57 The AML1/core binding factor beta (CBFbeta) transcription factor

58 We have expressed several variants of core binding factor beta (CBFbeta)-smooth muscle myosin

59 ty of Vif critically depends on the cellular core binding factor beta (CBFbeta).

60 e transcription factor fusion CBFbeta-SMMHC (core binding factor beta and the smooth-muscle myosin he

61 ng of most of the runt-related X1 co-factor, core binding factor beta fused to the smooth muscle myos

62 duct that fuses the first 165 amino acids of core binding factor beta to the coiled-coil region of a

63 in acts by dominantly interfering with AML-1/core binding factor beta-dependent transcriptional regul

64 K4b expression was caused by inv(16)-encoded core binding factor beta-smooth muscle myosin heavy chai

65 Core-binding factor beta (CBFbeta) and CBFalpha2 form a

66 The gene encoding for core-binding factor beta (CBFbeta) is altered in acute m

67 Core-binding factor beta (Cbfbeta) is the common non-DNA

68 Core-binding factor beta (CBFbeta) is the non-DNA-bindin

69 dimerization with another subunit called the core-binding factor beta (CBFbeta) subunit.

70 strong expression of RUNX1 and its cofactor, core-binding factor beta (CBFbeta), in megakaryocytes an

71 he presence of AML-1 and its partner protein core-binding factor beta in this osteoblast-restricted c

72 he RUNX1 Runt-Homology-Domain (RHD) with the core-binding factor beta protein (CBFbeta).

73 ts interaction with the transcription factor core-binding factor beta subunit (CBFbeta), and induces

74 eins and correlated with the binding of Runx/core-binding factor beta to regulatory elements within t

75 nd interacts with the AML-1-binding protein, core-binding factor beta.

76 ription factor 1 (RUNX1) and its associating core binding factor-beta (CBFB) play pivotal roles in le

77 The Runx1/core binding factor-beta (CBFbeta) transcriptional compl

78 os, c-Jun, osteoblast-specific factor-2, and core binding factor-beta increased the response to parat

79 tes transcription in part by helping recruit core binding factors, but nothing is known about the mec

80 minimal residual disease (MRD) monitoring in core binding factor (CBF) acute myeloid leukemia (AML) b

81 icated as a prognostic factor in adults with core binding factor (CBF) acute myeloid leukemia (AML).

82 ding the AML1 (RUNX1) or CBFbeta subunits of core binding factor (CBF) are commonly altered by transl

83 The inv(16) fuses the core binding factor (CBF) beta subunit with the coiled-c

84 eins, we found that the human enhancer bound core binding factor (CBF) between the muA and mu element

85 were, in 5'-to-3' order, a binding site for core binding factor (CBF) called core II, a binding site

86 AML1/RUNX1, a member of the core binding factor (CBF) family stimulates myelopoiesis

87 ing subunit of a transcription factor of the core binding factor (CBF) family, is required for the es

88 Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML

89 Core Binding Factor (CBF) is required for the developmen

90 Core binding factor (CBF) leukemias, those with transloc

91 Core binding factor (CBF) participates in specification

92 Runt domain is the DNA binding domain of the core binding factor (CBF) Runx subunits.

93 a luciferase gene, focusing initially on the core binding factor (CBF) site, which is footprinted in

94 Mutation of a core binding factor (CBF)-binding site at -288 decreased

95 binding protein CBFbeta as a complex termed core binding factor (CBF).

96 In the core binding factor (CBF)beta-smooth muscle myosin heavy

97 a binding site for the transcription factor core binding factor (CBF; also called AML1, PEBP2, and S

98 val, complex > or = 5, rare aberrations, and core-binding factor (CBF) abnormalities were prognostic

99 Core-binding factor (CBF) acute myeloid leukemia (AML) i

100 However, core-binding factor (CBF) AML treated with FLAG/DNX resu

101 served for t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) an

102 The core-binding factor (CBF) is a master regulator of devel

103 s with leukemogenic fusion proteins, such as core-binding factor (CBF) leukemia and MLL fusion leukem

104 t report of recurring FLT3 N676 mutations in core-binding factor (CBF) leukemias and suggests a defin

105 the DNA-binding subunit of the heterodimeric core-binding factor (CBF) that binds to the transcriptio

106 ties, including rearrangements involving the core-binding factor (CBF) transcriptional complex.

107 This fusion protein inhibits the core-binding factor (CBF), resulting in a block of hemat

108 The core-binding factor (CBF)-associated leukemia fusion pro

109 non-DNA-binding subunit of the heterodimeric core-binding factor (CBF).

110 betaRE and contains the transcription factor core-binding factor (CBF; also known as acute myeloid le

111 Core-binding factors (CBF) are heteromeric transcription

112 protein that binds the core site, one of the core-binding factors (CBF) is highly expressed in thymus

113 tectable in 165/1026 (16.1%) of aberrant non-core-binding-factor (CBF) karyotype patients.

114 RUNX1/CBFbeta (core binding factor [CBF]) is a heterodimeric transcript

115 The beta-subunit of core binding factor (CBFbeta), that heterodimerizes with

116 BFbeta is the non-DNA binding subunit of the core binding factors (CBFs).

117 Core-binding factors (CBFs) are a small family of hetero

118 Core-binding factors (CBFs) are a small family of hetero

119 Core-binding factors (CBFs) are a small family of hetero

120 B) is a DNA-binding subunit in the family of core-binding factors (CBFs), heterodimeric transcription

121 transcription factor in the small family of core-binding factors (CBFs).

122 mily of heterodimeric transcription factors, core-binding factors (CBFs).

123 DNA binding components of the heterodimeric core binding factor complex.

124 velopment, and situate an essential role for core-binding factors during the earliest stages of T-cel

125 that members of the activator protein-1 and core-binding factor families, binding to the activator p

126 es of hematopoiesis for which members of the core binding factor family are required, as well as the

127 bind members of the activator protein-1 and core-binding factor family of transcription factors, res

128 %): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormaliti

129 We examined the collective role of core-binding factors in hematopoiesis with a hypomorphic

130 The family of core-binding factors includes the DNA-binding subunits R

131 The Core Binding Factor is a heterodimeric transcription fac

132 Runx1 (AML1), the DNA binding subunit of a core binding factor, is required for the emergence and/o

133 Patients with core binding factor leukemia achieving complete remissio

134 The core binding factor leukemias with the translocations t(

135 Fbeta interaction as a therapeutic target in core binding factor leukemias.

136 of KIT occur in almost half of patients with core-binding factor leukemias, in which they have been a

137 acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBF alpha), and PEBP2 alpha

138 utations, KIT mutations, FLT3 mutations, and core binding factor rearrangements in AML, and JAK2 muta

139 on of nuclear factor, erythroid 2 (Nfe2) and core-binding factor, runt domain, alpha subunit 2, trans

140 aemogenic endothelium population whereas the core binding factor Runx1 (also known as AML1) is critic

141 nv(16)/t(16;16) rearrangements affecting the core-binding factors RUNX1 and CBFB, respectively, are f

142 ndependence in EMPs is not mediated by other core binding factors (Runx2 and/or Runx3); however, dele

143 significantly higher in AML-associated with core binding factor translocations or mutations in CEBPA

144 ized to one of three cytogenetic groups: (a) core binding factor type [(CBF); ie., t(8;21) inv(16), t